MX2010003872A - Bromhidrato de bupropion y aplicaciones terapeuticas. - Google Patents

Bromhidrato de bupropion y aplicaciones terapeuticas.

Info

Publication number
MX2010003872A
MX2010003872A MX2010003872A MX2010003872A MX2010003872A MX 2010003872 A MX2010003872 A MX 2010003872A MX 2010003872 A MX2010003872 A MX 2010003872A MX 2010003872 A MX2010003872 A MX 2010003872A MX 2010003872 A MX2010003872 A MX 2010003872A
Authority
MX
Mexico
Prior art keywords
relates
concrete
composition
effect
paste
Prior art date
Application number
MX2010003872A
Other languages
English (en)
Inventor
Paul Maes
Werner Oberegger
Mohammad Ashty Saleh
Graham Jackson
Original Assignee
Biovail Lab Int Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40521541&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010003872(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biovail Lab Int Srl filed Critical Biovail Lab Int Srl
Publication of MX2010003872A publication Critical patent/MX2010003872A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Materials For Medical Uses (AREA)

Abstract

Se describen formulaciones de bromhidrato de bupriopion as? como su uso para el tratamiento de afecciones.
MX2010003872A 2007-10-31 2008-10-28 Bromhidrato de bupropion y aplicaciones terapeuticas. MX2010003872A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/930,644 US7645802B2 (en) 2005-06-27 2007-10-31 Bupropion hydrobromide and therapeutic applications
PCT/EP2008/064619 WO2009056550A2 (en) 2007-10-31 2008-10-28 Bupropion hydrobromide and therapeutic applications

Publications (1)

Publication Number Publication Date
MX2010003872A true MX2010003872A (es) 2010-04-27

Family

ID=40521541

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003872A MX2010003872A (es) 2007-10-31 2008-10-28 Bromhidrato de bupropion y aplicaciones terapeuticas.

Country Status (13)

Country Link
US (3) US7645802B2 (es)
EP (1) EP2214650A2 (es)
JP (1) JP2011500865A (es)
KR (1) KR20100077182A (es)
CN (1) CN101903016A (es)
AU (1) AU2008320915B2 (es)
CA (1) CA2699588A1 (es)
CO (1) CO6270385A2 (es)
MX (1) MX2010003872A (es)
NI (1) NI201000044A (es)
RU (1) RU2485942C2 (es)
WO (1) WO2009056550A2 (es)
ZA (1) ZA201003036B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
EP1896002A4 (en) 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
UY31531A1 (es) * 2007-12-17 2009-08-03 Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr)
CA2934988A1 (en) * 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs
WO2010021718A1 (en) * 2008-08-19 2010-02-25 Nektar Therapeutics Complexes of small-interfering nucleic acids
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
ITMI20090190A1 (it) * 2009-02-13 2010-08-14 Dipharma Francis Srl Forma cristallina di bupropione bromidrato
US20120076865A1 (en) 2010-03-24 2012-03-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
KR101873075B1 (ko) * 2010-08-18 2018-06-29 에보니크 룀 게엠베하 하나 이상의 알긴산 염을 포함하는 위 내성 제약 또는 건강기능식품 제제
EP2601973A1 (en) * 2011-12-09 2013-06-12 Laboratoires SMB SA Dry powder formulation of azole derivative for inhalation
WO2015089150A1 (en) * 2013-12-10 2015-06-18 Forest Laboratories Holdings Limited Pharmaceutical formulations comprising vilazodone
ES2786312T3 (es) * 2014-11-26 2020-10-09 Evonik Operations Gmbh Composición farmacéutica o nutracéutica con resistencia contra la influencia de etanol
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
CA2978556C (en) * 2015-03-02 2022-02-15 Graphene 3D Lab Inc. Thermoplastic composites comprising water-soluble peo graft polymers useful for 3-dimensional additive manufacturing
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
CA3127871A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
EP3955936A1 (en) 2019-04-17 2022-02-23 COMPASS Pathfinder Limited Treatment of depression and other various disorders with psilocybin
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6033686A (en) * 1998-10-30 2000-03-07 Pharma Pass Llc Controlled release tablet of bupropion hydrochloride
US6096341A (en) * 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
US6238697B1 (en) * 1998-12-21 2001-05-29 Pharmalogix, Inc. Methods and formulations for making bupropion hydrochloride tablets using direct compression
US8545880B2 (en) * 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
US6337328B1 (en) * 1999-03-01 2002-01-08 Sepracor, Inc. Bupropion metabolites and methods of use
US6780871B2 (en) * 2001-01-29 2004-08-24 Albany Medical College Methods and compositions for treating addiction disorders
ES2336913T3 (es) * 2003-08-08 2010-04-19 Biovail Laboratories International Srl Comprimido de liberacion modificada de hidrocloruro de bupropion.
US7671094B2 (en) * 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
US7645802B2 (en) 2005-06-27 2010-01-12 Biovail Laboratories International Srl. Bupropion hydrobromide and therapeutic applications
EP1896002A4 (en) * 2005-06-27 2009-11-25 Biovail Lab Int Srl BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE
WO2007078895A2 (en) * 2005-12-30 2007-07-12 Biovail Laboratories International S.R.L. Modified release formulations of tramadol and uses thereof
US20090004281A1 (en) * 2007-06-26 2009-01-01 Biovail Laboratories International S.R.L. Multiparticulate osmotic delivery system
CA2934988A1 (en) * 2008-08-07 2010-02-11 Valeant International Bermuda Bupropion hydrobromide polymorphs

Also Published As

Publication number Publication date
US7645802B2 (en) 2010-01-12
US20130266650A1 (en) 2013-10-10
US20080274181A1 (en) 2008-11-06
ZA201003036B (en) 2011-07-27
NI201000044A (es) 2010-09-29
EP2214650A2 (en) 2010-08-11
KR20100077182A (ko) 2010-07-07
RU2485942C2 (ru) 2013-06-27
RU2010116863A (ru) 2011-12-10
CO6270385A2 (es) 2011-04-20
CA2699588A1 (en) 2009-05-07
AU2008320915A1 (en) 2009-05-07
WO2009056550A2 (en) 2009-05-07
JP2011500865A (ja) 2011-01-06
US20100255094A1 (en) 2010-10-07
CN101903016A (zh) 2010-12-01
AU2008320915B2 (en) 2013-05-09
WO2009056550A3 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
MX2010003872A (es) Bromhidrato de bupropion y aplicaciones terapeuticas.
WO2009056523A3 (fr) Composition formant en melange avec de l'eau une pâte pour la realisation d'un revetement decoratif sur un support et outils utilises a cette fin
CN105176220B (zh) 合成乳液硅藻内墙乳胶漆及其制备方法
CN101649150B (zh) 一种彩色闪光墙面漆及施工工艺
CN101586002A (zh) 彩色丽彩质感地坪漆及其施工工艺
CN101613570B (zh) 彩色绚彩质感地坪漆及施工工艺
JP5478834B2 (ja) 水性被覆材
CN109486456A (zh) 一种新型负离子释放型纳米水性环氧美缝剂
KR100912924B1 (ko) 석재뿜칠재 조성물과 그 제조방법 및 석재뿜칠재 조성물 시공 방법
CN109233508A (zh) 水包水仿大理石涂料及其制备方法和应用
US20060287414A1 (en) Acrylic plaster coating composition
CN104293037A (zh) 一种低光泽型环保罩面涂料及其制备方法
CN105062285B (zh) 一种单组份釉面墙面漆及其制备方法
KR101335689B1 (ko) 우레탄 컬러코팅 규사를 이용한 무광 무황변 무용제 에폭시 줄눈 및 미장제 조성물
JP6013162B2 (ja) 壁面仕上げ方法
JP2008208708A (ja) 壁面構造体
CN108047864A (zh) 一种质感涂料
JP6788260B2 (ja) 美爪料
AU2021106984A4 (en) Compositions and methods for joining two surfaces together
JP6645825B2 (ja) 仕上用モルタル
US1867180A (en) Cementitious composition and method of making same
JPS5835799Y2 (ja) プラスタ−ボ−ドの表面仕上部の構造
JP2013129771A (ja) 無機系塗料用のりおよび無機系塗料
CN201863461U (zh) 漆膜
GB2376229A (en) Plaster composition containing a colourant

Legal Events

Date Code Title Description
FG Grant or registration